Vitro Biopharma Inc. entered into definitive agreements with accredited investors for a private placement of a convertible promissory note and warrants to purchase shares of common shares for gross proceeds of $200,000 on April 14, 2023. The note will carry a coupon of 8% per annum, the convertible notes may be converted at any time at the option of the holder and are payable in full at the earliest of the completion of a qualified financing as defined below a change in control, or an event of default, or the maturity date, which is five years from the date of issuance.
1st Jan change | Capi. | |
---|---|---|
+2.97% | 94.74B | |
-3.68% | 37.28B | |
-12.37% | 32.68B | |
+74.21% | 27.72B | |
-14.15% | 16.19B | |
-2.48% | 13.88B | |
-12.21% | 11.58B | |
+188.83% | 10.92B | |
-53.94% | 9.54B |